title: Influence of two administration rates of alfaxalone at induction on its relative potency in cats: a pilot study.
abstract: Objectives The aim of the study was to evaluate, in a controlled, randomised, masked clinical trial, the influence of administration rate of alfaxalone at induction on its relative potency in cats and to report the incidence of cardiorespiratory adverse effects. Methods Twelve healthy female domestic cats admitted for ovariohysterectomy were premedicated with buprenorphine 20 µg/kg intramuscularly and alfaxalone 3.0 mg/kg subcutaneously. Sedation scores were established (using a published scale ranging from 1 [no sedation] to 5 [profound sedation]) prior to anaesthesia induction with alfaxalone intravenously at 2 mg/kg/min (group A2; n = 6) or 0.5 mg/kg/min (group A0.5; n = 6) to effect until orotracheal intubation was achieved. Sedation scores and alfaxalone induction doses were compared between the groups, using a Mann-Whitney exact test. Results are reported as median and range. Presence of apnoea (no breathing for more than 30 s) or hypotension (mean arterial blood pressure <60 mmHg) within 5 mins postintubation was also reported. Results Although sedation scores (1.5 [range 1.0-3.0] and 2.5 [range 1.0-3.0] for A2 and A0.5, respectively) were not significantly different ( P = 0.32), cats in group A2 required significantly more alfaxalone (4.3 mg/kg [range 3.4-7.0 mg/kg]) than group A0.5 (2.1 mg/kg [range 1.5-2.5 mg/kg]) ( P = 0.002). Two cats in each group presented postinduction apnoea, and two cats in group A2 and three cats in group A0.5 presented postinduction hypotension. Conclusions and relevance The use of a slower induction infusion rate resulted in an increase in the alfaxalone relative potency without obvious cardiorespiratory benefit.
authors.affiliation: Translational Research and Clinical Trials (TRACTs), Veterinary Hospital, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Werribee, VIC, Australia.
authors.forename: Sébastien H
authors.initials: SH
authors.lastname: Bauquier
authors.affiliation: Translational Research and Clinical Trials (TRACTs), Veterinary Hospital, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Werribee, VIC, Australia.
authors.forename: Leon N
authors.initials: LN
authors.lastname: Warne
authors.affiliation: Translational Research and Clinical Trials (TRACTs), Veterinary Hospital, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Werribee, VIC, Australia.
authors.forename: Jennifer E
authors.initials: JE
authors.lastname: Carter
authors.affiliation: Translational Research and Clinical Trials (TRACTs), Veterinary Hospital, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Werribee, VIC, Australia.
authors.forename: Ted
authors.initials: T
authors.lastname: Whittem
authors.affiliation: Translational Research and Clinical Trials (TRACTs), Veterinary Hospital, Faculty of Veterinary and Agricultural Sciences, The University of Melbourne, Werribee, VIC, Australia.
authors.forename: Thierry
authors.initials: T
authors.lastname: Beths
mesh_terms: D000758:Anesthesia / Q000662:veterinary*; D000762:Anesthesia Recovery Period; D000818:Animals; D002371:Cat Diseases / Q000188:drug therapy* / Q000601:surgery*; D002415:Cats; D005260:Female; D007044:Hysterectomy / Q000662:veterinary; D010052:Ovariectomy / Q000662:veterinary; D010865:Pilot Projects; D011277:Pregnanediones / Q000008:administration & dosage*; D012119:Respiration / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D011277:Pregnanediones; C006477:alphaxalone